Advertisements


FDA approves Takeda"s Alunbrig as first-line treatment for rare lung cancer

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 22nd, 2020

Roche"s Lung Cancer Drug Alecensa Gets Approval in China

The China National Drug Administration approves Roche's (RHHBY) cancer drug Alecensa as a monotherapy for first-line treatment of advanced non-small ce.....»»

Category: smallbizSource: nytAug 20th, 2018

FDA approves local biotech"s first rare-cancer drug

The FDA has approved the first-ever commercial cancer treatment from Cambridge biotech Epizyme Inc. Just a few years ago, Epizyme had given up on its potential cancer treatment and sold it to a Japanese drug company. On Thursday, the FDA approved the .....»»

Category: topSource: bizjournalsJan 23rd, 2020

Merck"s Keytruda Gets EU Approval for Difficult Lung Cancer

Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer po.....»»

Category: worldSource: nytMar 15th, 2019

EU approves Tagrisso as first-line treatment of certain lung cancers

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 8th, 2018

AstraZeneca"s Tagrisso Wins EU Nod for First-Line Lung Cancer

AstraZeneca's (AZN) Tagrisso gets an EU nod for first-line treatment of advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) m.....»»

Category: personnelSource: nytJun 11th, 2018

Merck"s Keytruda Gets Priority Review in Difficult Lung Cancer

Merck's (MRK) sBLA looking to expand the label of Keytruda for first-line treatment of metastatic squamous NSCLC gets FDA's priority review. The decisio.....»»

Category: worldSource: nytJul 3rd, 2018

AstraZeneca"s Thyroid Cancer Fail, Sarepta"s Clinical Hold, Takeda"s Front-Line Lung Cancer Win

AstraZeneca"s Thyroid Cancer Fail, Sarepta"s Clinical Hold, Takeda"s Front-Line Lung Cancer Win.....»»

Category: topSource: seekingalphaJul 28th, 2018

Pfizer Snatches FDA Approval For Rare Front-Line Lung Cancer Indication

Pfizer Snatches FDA Approval For Rare Front-Line Lung Cancer Indication.....»»

Category: topSource: seekingalphaOct 1st, 2018

The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.) read more.....»»

Category: blogSource: benzingaMay 7th, 2020

UroGen shares jump 10% on FDA approval of rare cancer treatment

Shares of UroGen Pharma Ltd. gained 10.7% in .....»»

Category: topSource: marketwatchApr 16th, 2020

UruGen shares jump 10% on FDA approval of rare cancer treatment

Shares of UroGen Pharma Ltd. gained 10.7% in .....»»

Category: topSource: marketwatchApr 16th, 2020

Bristol-Myers: Japan"s MHLW approves Opdivo for treatment of esophageal cancer

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 21st, 2020

The Margin: Rush Limbaugh says he has advanced lung cancer, vows to keep doing his show

Conservative lightning rod Rush Limbaugh told listeners on Monday that he has “advanced lung cancer” and will be missing shows for treatment......»»

Category: topSource: marketwatchFeb 3rd, 2020

FDA Fast Track on Lung Cancer Treatment Brings Exponential Gains for This Microcap Stock

When companies see their shares rise by 100% or more in a single day, it's usually because of a buyout or an extremely positive change in a company's future prospects. For Genprex, it was a nod from........»»

Category: blogSource: 247wallstJan 21st, 2020

Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug.

Just four days after Intrexon Corp. (NASDAQ: XON) made public plans to rebrand as Precigen, its subsidiary by the same name has secured a coveted regulatory designation for its blood cancer treatment. Germantown’s Precigen Inc. has earned orpha.....»»

Category: topSource: bizjournalsJan 6th, 2020

Spectrum Pharmaceuticals shares slide 57% after lung cancer trial misses goals

Shares of biopharmaceutical company Spectrum Pharmaceuticals Inc. slid more than 57% Thursday to mark their worst performance in 17 years, after the company said a mid-stage trial of a treatment for non-small cell lung cancer (NSCLC) missed its main goal......»»

Category: topSource: marketwatchDec 27th, 2019

UPDATE: Spectrum Pharma shares slide 47% premarket after trial of lung cancer treatment misses main goal

Spectrum Pharmaceuticals Inc. shares fell 47% in premarket trade Thursday after the company said a mid-stage trial of a treatment for non-small cell lung cancer, or NSCLC, missed its main goal. The Henderson, Nevada-bas.....»»

Category: topSource: marketwatchDec 26th, 2019

Spectrum Pharma shares slide 17% premarket after trial of lung cancer treatment misses main goal

Spectrum Pharmaceuticals Inc. shares fell 17% in premarket trade Thursday after the company said a mid-stage trial of a treatment for non-small cell lung cancer, or NSCLC, missed its main goal. The Henderson, Nevada-bas.....»»

Category: topSource: marketwatchDec 26th, 2019

FDA approves new treatment option for HER2-positive breast cancer patients

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 20th, 2019

Amgen granted orphan status for small cell lung cancer treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 19th, 2019